CIK 0001785279 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Metagenomi Therapeutics, Inc.
Sign in to watch- Ticker
- MGX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 813909017
- Phone
- (510) 871-4880
- Business address
- 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE, CA, 94608
- Former names
- Metagenomi, Inc., Metagenomi Technologies, LLC
- Open-market buys, last 90 days
- $23,401
- in 1 filing
- Open-market sales, last 90 days
- $5,107
- in 3 filings
Net +$18,294. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-06 | Noonberg Sarah B. Chief Medical Officer | Sale | −5,239 | $1.75 | $9K | 109,135 |
| 2025-06-06 | Wapnick Pamela Chief Financial Officer | Sale | −1,576 | $1.75 | $3K | 72,108 |
| 2025-06-06 | Thomas Brian C. Chief Executive Officer | Sale | −10,785 | $1.75 | $19K | 2,517,491 |
| 2025-06-06 | Irish Jian See Remarks | Sale | −6,390 | $1.75 | $11K | 315,543 |
| 2025-04-01 | Wapnick Pamela Chief Financial Officer | Grant or award | +14,000 | 73,684 | ||
| 2025-04-01 | Wapnick Pamela Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +84,000 | 84,000 | ||
| 2025-04-01 | Thomas Brian C. Chief Executive Officer | Grant or award | +32,000 | 2,528,276 | ||
| 2025-04-01 | Thomas Brian C. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +196,000 | 196,000 | ||
| 2025-04-01 | Irish Jian See Remarks | Grant or award | +23,000 | 321,933 | ||
| 2025-04-01 | Irish Jian See Remarks | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2025-04-01 | Wein Matthew See Remarks | Grant or award | +3,650 | 13,117 | ||
| 2025-04-01 | Wein Matthew See Remarks | Grant or award | +3,775 | 16,892 | ||
| 2025-04-01 | Wein Matthew See Remarks | Grant or award · Stock Option (Right to Buy) | +21,875 | 21,875 | ||
| 2025-04-01 | Wein Matthew See Remarks | Grant or award · Stock Option (Right to Buy) | +22,725 | 22,725 | ||
| 2025-04-01 | Noonberg Sarah B. Chief Medical Officer | Grant or award | +14,000 | 114,374 | ||
| 2025-04-01 | Noonberg Sarah B. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +84,000 | 84,000 | ||
| 2025-03-05 | Wein Matthew See Remarks | Sale | −930 | $1.87 | $2K | 9,467 |
| 2025-03-05 | Wapnick Pamela Chief Financial Officer | Sale | −1,808 | $1.87 | $3K | 59,684 |
| 2025-02-03 | BJERKHOLT ERIC Director | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2024-12-05 | Wapnick Pamela Chief Financial Officer | Sale | −1,559 | $1.86 | $3K | 61,492 |
Page 3 of 6 · 101 trades